Palmitoylethanolamide (PEA) 300mg Capsules 100
Palmitoylethanolamide (PEA) is a natural painkiller used worldwide by more than a million people. For more than 50
years (since 1957), successful studies have been made into its effectiveness. These studies have shown that PEA is a
positive and natural substance produced by the body; it is very effective and safe to use.
Palmitoylethanolamide (PEA), an endogenous fatty acid amide, has been demonstrated to perform a great variety of
biological functions related to chronic and neuropathic pain and inflammation, as has been demonstrated in clinical
trials. These include peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral
neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental
pains, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, post-herpetic neuralgia, and vaginal
PEA is an endogenous modulator and is natural compound found in food, such as eggs and milk. PEA has had no
serious side effects reported, nor any drug–drug interactions, thus is very well tolerated. PEA can be taken together
with other medicines.
Dosage: Take 2 capsules twice daily, with or without food. The content of the capsule may be sprinkled onto food if
desired, and taken this way. Alternatively, the contents of the capsules may be placed under the tongue for a few
minutes before swallowing, to enhance relief of severe pain or migraine.
The dose of PEA may be increased, up to a maximum of 16 capsules per day for an adult if necessary. I.e. 100mg/kg
Maximum pain reduction may take up to 3 months for severe pain.
PEA has been used synergistically with other pain treatments and has been shown to reduce the reliance on narcotic
Reference: peer review journals
- Keppel Hesselink, J.M. 2012. New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. Open Pain Journal 5: 12-23
- Keppel Hesselink, J.M., Hekker, T.A. 2012. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series Journal of Pain Research 5:437 – 442
- Keppel Hesselink JM, Kopsky DJ, Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells. Journal of Pain Research 2013
- Keppel Hesselink JM. Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. International Medical Case Reports Journal Published Date September 2013 Volume 2013:6 Pages 49 – 53
- Keppel Hesselink JM, Kopsky DJ.J Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147/JPR.S93106. Review. https://www.ncbi.nlm.nih.gov/pubmed/?term=Keppel%20Hesselink%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=26604814